New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
04:55 EDTZIOP, ZIOP, PFE, PFE, ALKS, ALKS, TEVA, TEVA, SNY, SNY, GSK, GSK, MRK, MRK, RHHBY, RHHBY, BAYRY, BAYRY, DRNA, DRNA, KBIO, KBIO, ABBV, ABBVBoston Biotech Conference to hold a conference
Boston CEO Conference to be held in Boston on June 4-5.
News For ABBV;KBIO;DRNA;BAYRY;RHHBY;MRK;GSK;SNY;TEVA;ALKS;PFE;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 17, 2015
07:33 EDTABBVOraSure 44% year-to-date selloff overdone, says Jefferies
Subscribe for More Information
07:25 EDTABBV, PFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
07:14 EDTRHHBYProthena announces PRX002 was safe, well tolerated
Subscribe for More Information
07:12 EDTTEVANeurocrine price target raised to $87 from $63 at Piper Jaffray
Subscribe for More Information
05:32 EDTABBVAbbVie initiated with an Overweight at Piper Jaffray
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
05:31 EDTMRKMerck initiated with a Neutral at Piper Jaffray
Subscribe for More Information
June 16, 2015
14:23 EDTTEVAReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.
14:12 EDTTEVAAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
13:16 EDTGSKFDA appoves labeling changes for GSK anti-seizure drug
Subscribe for More Information
11:16 EDTALKSAlkermes says company doesn't comment on rumors, Feuerstein reports
Strength in shares of Alkermes (ALKS) this morning is being attributed by traders to speculation of a takeover. A company spokesperson reportedly told TheStreet's Adam Feuerstein that the company does not comment on rumors or speculation. Shares of Alkermes are up $4.70, or about 8%, to $63.29 in late morning trading. Reference Link
11:06 EDTTEVATeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
10:29 EDTTEVAGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
10:07 EDTMRK, ALKSAlkermes spike attributed to takeover speculation
The spike higher in shares of Alkermes (ALKS) is being attributed by traders to speculation of a takeover. Shares jumped 6% to $61.89 in morning trading. The Ireland based drugmaker focuses on treatments of central nervous system disorders, such as addiction, schizophrenia and depression. The speculative chatter has Merck (MRK) as a potential acquirer of Alkermes. The company’s June 60 and 65 calls are actively trading, according to The Fly's options specialist.
10:06 EDTALKSHigh option volume stocks
Subscribe for More Information
10:01 EDTALKSAlkermes calls active
Alkermes June 60 and 65 calls are active on total call volume of 800 contracts (0 puts) on renewed takeover chatter. June call option implied volatility is at 75, July is at 46, August is at 45; compared to its 52-week range of 33 to 59. Active call volume suggests traders taking positions for large price movement.
09:55 EDTALKSRumor: Alkermes shares active on renewed takeover speculation
Subscribe for More Information
08:05 EDTTEVATeva reports ARM-TD study meets primary endpoint
Teva Pharmaceutical (TEVA) announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia, or ARM-TD, designed to evaluate the efficacy of SD-809 in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale, or AIMS, from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy compared to 1.6 points in placebo for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo experienced serious adverse events. Three patients discontinued from the study for adverse events. For all other side effects reported in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication, the company said. SD-809 became part of Teva’s central nervous system product portfolio with the acquisition of Auspex Pharmaceuticals in May.
07:31 EDTTEVAEagle Pharmaceuticals price target raised to $95 from $65 at Cantor
Subscribe for More Information
06:23 EDTBAYRYAcura enters into agreement with Pharma Bayer for IMPEDE
Acura Pharmaceuticals (ACUR) announced that Acura has entered into a License and Development Agreement with Bayer Healthcare (BAYRY) to provide an exclusive worldwide license to Acura's IMPEDE technology for use in an undisclosed methamphetamine resistant pseudoephedrine containing product and to jointly develop such product utilizing the IMPEDE technology for the U.S. market. Bayer has the right to negotiate for a worldwide license to the IMPEDE technology for additional products.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use